Mouse anti-HA tag mAb, clone 98-106
Mouse anti-HA tag mAb is specific to YPYDVPDYA (HA) tag which can be applied
to several immunoassays including ELISA, WB, IP, IFA and FACS. This antibody
has been identified in several sources (bacteria, yeast and mammalian cells) of
HA tag fusion protein.
to several immunoassays including ELISA, WB, IP, IFA and FACS. This antibody
has been identified in several sources (bacteria, yeast and mammalian cells) of
HA tag fusion protein.
Product type:
Monoclonal, clone 98-106
Concentration:
0.5 mg/mL
Immunogen:
Peptide: YPYDVPDYA (HA)
Host:
Mouse
Reactivity:
Recognizes HA tag on either the N- or C-terminus of recombinant fusion protein.
Form:
Liquid
Storage Buffer:
Phosphate Buffered Saline containing 50% glycerol and 0.02% sodium azide.
Storage:
Store at 4°C for at least 6 months.
Store at -20°C for long-term preservation. Avoid repeated freeze/thaw cycles.
Suggestion: Divide antibody into several vials. Keep only vials for usage at 4°C.
Application:
ELISA, WB, IP, IFA, FACS
Manual:
Note: Application concentration may be various determined by the end user.
Shipping Conditions:
Blue ice
Monoclonal, clone 98-106
Concentration:
0.5 mg/mL
Immunogen:
Peptide: YPYDVPDYA (HA)
Host:
Mouse
Reactivity:
Recognizes HA tag on either the N- or C-terminus of recombinant fusion protein.
Form:
Liquid
Storage Buffer:
Phosphate Buffered Saline containing 50% glycerol and 0.02% sodium azide.
Storage:
Store at 4°C for at least 6 months.
Store at -20°C for long-term preservation. Avoid repeated freeze/thaw cycles.
Suggestion: Divide antibody into several vials. Keep only vials for usage at 4°C.
Application:
ELISA, WB, IP, IFA, FACS
Manual:
| Application | Dilution factor | Final concentration |
| ELISA | 1:5000-20000 | 0.05-0.2 μg/mL |
| WB | 1:1000-10000 | 0.1-1 μg/mL |
| IP | 1:500-2000 | 0.5-2 μg/mL |
| IFA | 1:500-1000 | 1-2 μg/mL |
| FACS | 1:500-1000 | 1-2 μg/mL |
Shipping Conditions:
Blue ice
1.
Cheng YW, Chuang YC, Huang SW, Liu CC, Wang JR. An auto-antibody identified from phenotypic directed screening platform shows host immunity against EV-A71 infection. J Biomed Sci. 2022 Feb 8;29(1):10.
2.
Huang SW, Tai CH, Hsu YM, Cheng D, Hung SJ, Chai KM, Wang YF, Wang JR. Assessing the application of a pseudovirus system for emerging SARS-CoV-2 and re-emerging avian influenza virus H5 subtypes in vaccine development. Biomed J. 2020 Aug;43(4):375-387.
Cheng YW, Chuang YC, Huang SW, Liu CC, Wang JR. An auto-antibody identified from phenotypic directed screening platform shows host immunity against EV-A71 infection. J Biomed Sci. 2022 Feb 8;29(1):10.
2.
Huang SW, Tai CH, Hsu YM, Cheng D, Hung SJ, Chai KM, Wang YF, Wang JR. Assessing the application of a pseudovirus system for emerging SARS-CoV-2 and re-emerging avian influenza virus H5 subtypes in vaccine development. Biomed J. 2020 Aug;43(4):375-387.